Initial use of risperidone in the treatment of acutely exacerbated schizophrenic patients - An interim analysis;Initialtherapie mit risperidon in der akutbehandlung schizophrener patienten - Eine interimsanalyse

Fortschritte der Neurologie Psychiatrie

Volumn 71, Issue 5, 2003, Pages 249-254

  Pajonk, F G ^a   Schreiner, A ^b   Peters, S ^b   Rettig, K ^c   Degner, D ^d   Ruther E ^d  

^a SAARLAND UNIVERSITY   (Germany)

^b JANSSEN CILAG GMBH   (Germany)

^c Medizin mbH   (Germany)

^d UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; RISPERIDONE;

ACUTE DISEASE; ADULT; AGGRESSION; AGITATION; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; CONTROLLED STUDY; COOPERATION; DISEASE EXACERBATION; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EXCITATION; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HOSTILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MUSCLE HYPOTONIA; NEGATIVE SYNDROME; SCHIZOPHRENIA; SEXUAL DYSFUNCTION; SYMPTOMATOLOGY; TREATMENT OUTCOME; TREATMENT PLANNING;

ACUTE DISEASE; ADULT; AGGRESSION; ANTIPSYCHOTIC AGENTS; FEMALE; HUMANS; MALE; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; PSYCHOMOTOR AGITATION; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 0037937512     PISSN: 07204299     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-39063     Document Type: Article

References (26)

1. Möller HJ. Aktuelle Bewertung neuer/atypischer Neuroleptika. Nervenarzt 2000; 71: 329-344
2. Naber D, Lambert M, Krausz M, Haasen C. Atypische Neuroleptika in der Behandlung schizophrener Patienten. Bremen: UNI-MED Verlag, 2000
3. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatr 1994; 151: 625-835
4. Peuskens J. Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group. Br J Psychiatry 1995; 166: 712-726
5. Blin O, Azorin JM, Bouhours P. Antipsychotic and anxiolytic properties of risperidone, haloperidol, and methotrimeprazine in schizophrenic patients. J Clin Psychopharamcol 1996; 16: 38-44
6. Hoyberg OJ, Fensbo C, Remvig J, Lingjaerde O, Sloth-Nielsen M, Salveses I. Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acut exacerbations. Acta Psychiatr Scand 1993; 88 (6): 395-402
7. Huttunen MO, Piepponen T, Rantanen H, Lamo I, Nyhom R, Raitasuo V. Risperidone versus zuclopenthixol in the treatment of acute schizophrenic episodes: a double-blind parallel-group trial. Acta Psychiatr Scand 1995; 91: 271-277
8. Ceskova E, Swestka J. Double-blind comparison of risperidone and haloperidol in schizophrenic and schizoaffective psychoses. Pharmacopsychiatry 1993; 26: 121-124
9. Currier GW, Simpson MD. Risperidone liquid concentrate and oral lorazepam versus haloperidol and intramuscular lorazepam for treatment of psychotic agitation. J Clin Psychiatry 2001; 61: 153-157
10. Czobor P, Volavka J, Mibach RC. Effect of risperidone on hostility in schizophrenia. J Clin Psychopharmacol 1995; 15: 243-249
11. Chengappa KNR, Levine J, Ultich R, Parepelly H, Brars JS, Atzert R, Brienzo R, Gopelani A. Impact of risperidone on seclusion and restraint in a state psychiatric hospital. Can J Psychiatry 2000; 45: 827-832
12. Buckley PF, Ibrahim ZY, Singer B, Orr B, Donenwirth K, Brars PS. Aggression and schizophrenia: efficacy of risperidone. J Am Acad Psychiatry Law 1997; 25: 173-181
13. Beck NC, Greenfield SR, Gotham H, Mendito AA, Stuve P, Hemme CA. Risperidone in the management of violent, treatment-resistant schizophrenics hospitalized in a maximum security forensic facility. J Am Acad Psychiatry Law 1997; 25: 461-468
14. Keck PE, Strakowski SM, McElroy SL. The efficacy of atypical antipsychotics in the treatment of depressive symptoms, hostility, and suicidality in patients with schizophrenia. J Clin Psychiatry 2000; 61 (Suppl 3): 4-8
15. Currier GW. Atypical Antipsychotic Medications in the psychiatric emergency service. J Clin Psychiatry 2000; 61 (Suppl 14): 21-26
16. McCreadie RG. Managing the first episode of schizophrenia: the role of new therapies. European Neuropsycophamacology 1996; 6: 2-5
17. Csernansky JG, Mahmoud R, Brenner R. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. New England Journal of Medicine 2002; 346: 16-22
18. Kane J. Factors which can make patients difficult to treat. Br J Psychiatry 1996; 196 (Suppl) 31: 10-14
19. Rabinowitz J, Lichtenberg P, Kaplan Z, Mark M, Nahon D. Rehospitalization rate of chronically ill schizophrenic patients discharged on a regimen of risperidone, olanzapine, or conventionel antipsychotics. Am J Psychiatry 2001; 158: 266-269
20. Linden M, Baier D, Beitinger H, Kohnen R, Osterheider M, Philipp M, Reimitz DE, Schaaf B, Weber HJ. Guidelines for the implementation of drug utiliziation observation (DUO) studies in psychopharmacological therapy. The "Phase IV Research" Task-Force of the Association for Neuropsychopharmacology and Pharmacopsychiatry (AGNP). Pharmacopsychiatry 1997; 30 (1 Suppl): 65-70
21. Pajonk FG, Holzbach R, Naber D. Comparing the efficacy of atypical antipsychotics in open uncontrolled versus double-blind controlled trials in schizophrenia. Psychopharmacology 2002; 162: 29-36
22. Gerlach J. Life is not so easy (Editorial). Psychopharmacology 2002; 162: 1-2
23. Williams R. Optimal dosing with risperidone: updated recommendations. J Clin Psychiatry 2001; 62: 282-289
24. Campbell R, Simpson GM. Alternative approaches in the treatment of psychotic agitation. Psychosomatics 1986; 27: 23-27
25. Dubin WR. Rapid tranquilization: antipsychotics or benzodiazepines? J Clin Psychiatry 1988; 49 (Suppl 12): 210-222
26. Foster S, Kessel J, Berman ME, Simpson GM. Efficacy of lorazepam and haloperidol for rapid tranquilization in a psychiatric emergency room setting. Int Clin Psychopharmacol 1997; 12: 175-179